4.3 Clinical Toxicology, Overdose Management, and Antidotes

4.3 Clinical Toxicology, Overdose Management, and Antidotes

Clinical toxicology encompasses the rapid evaluation, resuscitation, diagnosis, and antidote-directed management of drug overdoses and chemical poisonings. The PEBC Evaluating Examination frequently tests toxic mechanisms, toxidrome differentiation, decontamination limits, and specific antidote pharmacotherapy.

---

1. General Principles of Resuscitation and Decontamination

Emergency toxicological stabilization prioritizes the clinical "ABCDEs" (Airway, Breathing, Circulation, Disability, Exposure), correction of hypoglycemia (dextrose), thiamine administration in suspected alcoholism/Wernicke encephalopathy, and targeted antidote delivery.

+--------------------------------------------------------------------------------------+
|                     GASTROINTESTINAL DECONTAMINATION MODALITIES                      |
+--------------------------------------------------------------------------------------+
|  1. Single-Dose Activated Charcoal (SDAC: 1 g/kg PO/NG within 1-2 hours)             |
|     - Ineffective: Iron, Lithium, Lead, Toxic Alcohols, Strong Acids/Alkalis (PHAILS)|
|     - Contraindicated: Unprotected airway, bowel perforation, hydrocarbon ingestion |
|                                                                                      |
|  2. Multiple-Dose Activated Charcoal (MDAC: 0.5 g/kg q2-4h)                          |
|     - Effective for: Carbamazepine, Dapsone, Phenobarbital, Quinine, Theophylline    |
|                                                                                      |
|  3. Whole Bowel Irrigation (WBI: PEG-ELS 1.5-2 L/h until clear effluent)             |
|     - Indications: Sustained-release tablets, Iron, Lithium, Illicit Body Packers   |
|                                                                                      |
|  4. Urinary Alkalinization (IV NaHCO3 targeting urine pH 7.5 - 8.5)                  |
|     - Indications: Salicylates, Phenobarbital, Methotrexate                          |
|     - Prerequisite: Must correct hypokalemia (K+) to prevent paradoxical aciduria    |
+--------------------------------------------------------------------------------------+

Extracorporeal Enhanced Elimination (Hemodialysis)

Hemodialysis efficiently eliminates toxins with low molecular weight ($<500\text{ Da}$), low protein binding ($<70-80\%$), high water solubility, and a small apparent volume of distribution ($V_d < 1\text{ L/kg}$):

$$\mathbf{\text{Indications for Hemodialysis ("I STUMBLE")}}: \begin{cases} \mathbf{I} & \text{Isopropanol (refractory hypotension)} \\ \mathbf{S} & \text{Salicylates (level } > 6.5-7.2\text{ mmol/L [}90-100\text{ mg/dL], coma, ARDS)} \\ \mathbf{T} & \text{Theophylline (acute level } > 500\text{ }\mu\text{mol/L [}90-100\text{ mg/L])} \\ \mathbf{U} & \text{Uremia} \\ \mathbf{M} & \text{Methanol (level } > 15-20\text{ mmol/L, visual defects, severe acidosis)} \\ \mathbf{B} & \text{Barbiturates (phenobarbital with refractory shock/coma)} \\ \mathbf{L} & \text{Lithium (level } > 4.0\text{ mmol/L acute, or } > 2.5\text{ chronic with neurotoxicity)} \\ \mathbf{E} & \text{Ethylene Glycol (level } > 15-20\text{ mmol/L, renal failure, severe acidosis)} \end{cases}$$

---

2. Clinical Toxidrome Differentiation

A toxidrome is a constellation of clinical signs and symptoms characteristic of a specific pharmacological class of poison:

Serotonin Syndrome vs. Neuroleptic Malignant Syndrome vs. Malignant Hyperthermia

+--------------------------------------------------------------------------------------+
|                 HYPERTHERMIC TOXICOLOGICAL EMERGENCIES MATRIX                        |
+--------------------------------------------------------------------------------------+
|  SEROTONIN SYNDROME (SS):                                                            |
|  - Etiology : Serotonergic excess (SSRIs + MAOIs, TCAs, Tramadol, Linezolid, Fentanyl) |
|  - Onset    : Rapid (<24 hours)                                                      |
|  - Features : Spontaneous / Inducible CLONUS, Hyperreflexia (legs > arms), Diaphoresis|
|  - Treatment: Stop agents, Benzodiazepines, Cyproheptadine (5-HT2A antagonist)       |
|                                                                                      |
|  NEUROLEPTIC MALIGNANT SYNDROME (NMS):                                               |
|  - Etiology : Dopamine D2 blockade (Antipsychotics) or DA agonist withdrawal         |
|  - Onset    : Gradual (days to weeks)                                                |
|  - Features : "LEAD-PIPE" Rigidity, Hyporeflexia, Extreme Hyperthermia, High CK / WBC |
|  - Treatment: Stop neuroleptic, ICU cooling, Bromocriptine (DA agonist), Dantrolene  |
|                                                                                      |
|  MALIGNANT HYPERTHERMIA (MH):                                                        |
|  - Etiology : RYR1 receptor mutation triggered by Volatile Anesthetics / Succinylcholine
|  - Features : Masseter spasm, rapid hyperthermia, metabolic acidosis, rhabdomyolysis |
|  - Treatment: Discontinue trigger, 100% O2, IV Dantrolene (1-2.5 mg/kg boluses)      |
+--------------------------------------------------------------------------------------+

---

3. High-Yield Specific Toxicities and Mechanisms

Acetaminophen (APAP) Hepatotoxicity and N-Acetylcysteine

Acetaminophen is metabolized at therapeutic doses via glucuronidation ($50-60\%$) and sulfation ($30-40\%$). A small fraction ($<10\%$) is oxidized by CYP2E1 to the highly reactive electrophile N-acetyl-p-benzoquinone imine (NAPQI), which is rapidly detoxified by conjugation with endogenous hepatic glutathione.

                   [Acetaminophen (Toxic Ingestion)]
                                  |
           +----------------------+----------------------+
           | (Saturated Pathways)                        | (Shunted Pathway)
           v                                             v
[Phase II Glucuronide / Sulfate]                    [CYP2E1]
      (Non-Toxic)                                        |
                                                         v
                                                      [NAPQI]
                                                         |
                           +-----------------------------+-----------------------------+
                           |                                                           |
                           v (+ Hepatic Glutathione / NAC)                             v (Glutathione Stores <30%)
               [Mercapturic Acid / Cysteine Conjugate]                  [Covalent Binding to Hepatocyte Proteins]
                         (Non-Toxic Urine Excretion)                                   |
                                                                                       v
                                                                           [Centrilobular Hepatic Necrosis]

• The Rumack-Matthew Nomogram: Evaluates hepatotoxicity risk strictly for single acute ingestions with known ingestion time between $4$ and $24\text{ hours}$.
  • The Canadian treatment line starts at $1000\text{ }\mu\text{mol/L}$ ($150\text{ mcg/mL}$) at $4\text{ hours}$ post-ingestion.
• N-Acetylcysteine (NAC) Mechanism: Replenishes hepatic glutathione stores, serves as a direct glutathione surrogate, enhances non-toxic sulfation, and improves microcirculatory perfusion.
• Dosing Protocols: Intravenous 21-hour 3-bag protocol ($150\text{ mg/kg}$ over $1\text{ h}$, $50\text{ mg/kg}$ over $4\text{ h}$, $100\text{ mg/kg}$ over $16\text{ h}$) or simplified 2-bag protocol ($200\text{ mg/kg}$ over $4\text{ h}$, $100\text{ mg/kg}$ over $16\text{ h}$). NAC is continued beyond standard infusion until APAP is undetectable, ALT/AST are normal or clearly declining, and INR $<1.5$.

Salicylate (Aspirin) Toxicity

Salicylates exhibit complex biphasic acid-base derangements:

1. Early Phase: Direct stimulation of the medullary respiratory center causes hyperventilation and a primary respiratory alkalosis.
2. Late Phase: Uncoupling of mitochondrial oxidative phosphorylation, inhibition of Krebs cycle dehydrogenases, and stimulation of lipolysis lead to accumulation of lactic acid, pyruvate, and ketoacids, producing a primary high anion gap metabolic acidosis.
3. Net Clinical State: Mixed Primary Respiratory Alkalosis and Primary High Anion Gap Metabolic Alkalosis.

• Management: Volume resuscitation, IV Sodium Bicarbonate infusion (targets urine $\text{pH } 7.5-8.5$ to trap ionized salicylate in tubular fluid), mandatory potassium repletion, and emergent hemodialysis for severe poisonings (salicylate $>6.5-7.2\text{ mmol/L}$, altered mental status, pulmonary edema, or renal failure).

Toxic Alcohols: Methanol vs. Ethylene Glycol vs. Isopropanol

$$\text{Osmolal Gap} = \text{Measured Osmolality} - \left(2 \cdot [\text{Na}^+] + [\text{Glucose}] + [\text{Urea}]\right) \quad (\text{Normal } < 10-15\text{ mOsm/kg})$$

---

4. Comprehensive Antidote Master Table